Cargando…
Immunological Subpopulations Within Critically Ill COVID-19 Patients
Autores principales: | Wilson, Julie Kay, Shankar-Hari, Manu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889441/ https://www.ncbi.nlm.nih.gov/pubmed/33609517 http://dx.doi.org/10.1016/j.chest.2021.01.023 |
Ejemplares similares
-
Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials
por: Shankar-Hari, Manu, et al.
Publicado: (2020) -
Compartmentalisation of immune responses in critical illness: does it matter?
por: Conway Morris, Andrew, et al.
Publicado: (2022) -
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
por: Tatham, Kate C., et al.
Publicado: (2021) -
How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?
por: Shankar-Hari, M.
Publicado: (2017) -
Into the limelight: TPA for critically ill Covid‐19 patients
por: Abbas, Eslam, et al.
Publicado: (2022)